[Cancer treatment-induced bone loss. Treatment for breast cancer].
Progress in cancer research and multidisciplinary therapy has led to improvements in prognosis for cancer patients. Bone health has been regarded as important in terms of long-term quality of life. Lately, cancer treatment-induced bone loss (CTIBL) associated with endocrine therapy, chemotherapy, and radiotherapy has attracted considerable attention. In this article we introduce the latest results of clinical trials around the world on CTIBL associated with breast cancer treatment, in particular aromatase inhibitor associated bone loss (AIBL) . We also explain the efficacy of using bisphosphonate or Denosumab with endocrine therapy, the latest management strategy for bone health.
Yamada
Kimito
K
Tokyo Medical University, Department of Breast Oncology.
Kohno
Norio
N
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D015519:Bone Density; D001862:Bone Resorption / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D001943:Breast Neoplasms / Q000628:therapy*; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D010024:Osteoporosis / Q000209:etiology; D053245:RANK Ligand / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab